
Trump Threatens 35% Tariffs if Brussels Backtracks on $600 Billion Investment Promise
Von der Leyen has already admitted that she may have overpromised in the name of member states.

Von der Leyen has already admitted that she may have overpromised in the name of member states.

The implications of the agreement on the pharmaceutical industry remain “uncertain” and could “harm patients.”